van den Heuvel A F, van Veldhuisen D J, Bartels G L, van der Ent M, Remme W J
Sticares Research Foundation, Rotterdam, The Netherlands.
Eur Heart J. 1999 Dec;20(23):1717-23. doi: 10.1053/euhj.1999.1710.
In patients with coronary artery disease acetylcholine (a muscarinic agonist) causes vasoconstriction. The effect of atropine (a muscarinic antagonist) on coronary vasotone in patients with normal or impaired left ventricular function is unknown.
Twenty-four patients who required atropine infusion (to supplement heart rate response) during atrial pacing (pacing was conducted to assess ischaemia as part of an experimental protocol) were studied; 17 patients had normal and seven impaired left ventricular function (ejection fraction < or =0.40). Two control groups were selected from a large database (from patients in whom atrial pacing was carried out but to whom atropine was not administered) to match the normal (n=20) and dysfunction (n=10) groups. In the normal left ventricular function group atropine increased rate pressure product by 12 +/- 4%, as compared to those without atropine (P < 0.05). Left ventricular end diastolic pressure increased less in the atropine group (+40 +/- 8% vs +78 +/- 6%;P < 0.05). Arterial norepinephrine increased similarly in both groups, but coronary flow (as assessed by using a thermodiluting method in the coronary sinus) increased 23 +/ -4% more in the atropine group (P < 0.05). Further, there were lower levels of myocardial lactate production and ST-segment depression in the atropine group [lactate extraction +13 +/- 6% (atropine) vs -19 +/- 4% (controls), ST-segment depression 1. 3 +/- 0.6 (atropine) vs 1.8 +/- 0.2 mm (control), both P < 0.05 between groups]. In contrast, in the dysfunction group the overall effect of atropine was less pronounced.
In patients with normal left ventricular function atropine improves coronary flow and reduces myocardial lactate production and ST-segment depression during atrial pacing, suggesting a reduction in myocardial ischaemia.
在冠心病患者中,乙酰胆碱(一种毒蕈碱激动剂)会引起血管收缩。阿托品(一种毒蕈碱拮抗剂)对左心室功能正常或受损患者冠状动脉张力的影响尚不清楚。
对24例在心房起搏期间需要输注阿托品(以补充心率反应)的患者进行了研究(起搏作为实验方案的一部分用于评估缺血情况);17例患者左心室功能正常,7例左心室功能受损(射血分数≤0.40)。从一个大型数据库中选取两个对照组(来自进行了心房起搏但未给予阿托品的患者),以匹配正常组(n = 20)和功能障碍组(n = 10)。在左心室功能正常组中,与未使用阿托品的患者相比,阿托品使心率血压乘积增加了12±4%(P < 0.05)。阿托品组左心室舒张末期压力升高幅度较小(分别为+40±8%和+78±6%;P < 0.05)。两组动脉去甲肾上腺素升高情况相似,但阿托品组冠状动脉血流(通过冠状窦热稀释法评估)增加幅度多23±4%(P < 0.05)。此外,阿托品组心肌乳酸生成水平和ST段压低程度较低[乳酸摄取+13±6%(阿托品组)对-19±4%(对照组),ST段压低1.3±0.6(阿托品组)对1.8±0.2 mm(对照组),两组间均P < 0.05]。相比之下,在功能障碍组中,阿托品的总体作用不太明显。
在左心室功能正常的患者中,阿托品可改善心房起搏期间的冠状动脉血流,减少心肌乳酸生成和ST段压低,提示心肌缺血减轻。